Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
- Author
- YAMAUCHI, Takahiro1 ; NEGORO, Eiju1 ; UEDA, Takanori1 ; ARAI, Hajime1 ; IKEGAYA, Satoshi1 ; TAKAGI, Kazutaka1 ; TAKEMURA, Haruyuki1 ; INAI, Kunihiro1 ; YOSHIDA, Akira1 ; URASAKI, Yoshimasa1 ; IWASAKI, Hiromichi1
[1] Department of Hematology and Oncology, University of Fukui, 23 Shimoaizuki, Matsuoka, Eiheiji, Fukui 910-1193, Japan - Source
Anticancer research. 2007, Vol 27, Num 4C, pp 2635-2639, 5 p ; ref : 25 ref
- ISSN
- 0250-7005
- Scientific domain
- Medical oncology
- Publisher
- International Institute of Anticancer Research, Attiki
- Publication country
- Greece
- Document type
- Article
- Language
- English
- Author keyword
- AML Cytarabine MDS elderly patients melphalan mitoxantrone
- Keyword (fr)
- Age Anticancéreux Cancérologie Cytarabine Dose faible Melphalan Mitoxantrone Myélodysplasique syndrome Personne âgée Risque élevé Leucémie aiguë myéloblastique Agent alkylant Anthraquinone dérivé Antimétabolite Homme Hémopathie maligne Moutarde à l'azote Pyrimidine nucléoside
- Keyword (en)
- Age Antineoplastic agent Cancerology Cytarabine Low dose Melphalan Mitoxantrone Myelodysplastic syndrome Elderly High risk Acute myelocytic leukemia Alkylating agent Anthraquinone derivatives Antimetabolic Human Malignant hemopathy Nitrogen mustard Pyrimidine nucleoside
- Keyword (es)
- Edad Anticanceroso Cancerología Citarabina Dosis débil Melfalán Mitoxantrona Mielodisplastico síndrome Anciano Riesgo alto Leucemia mieloblástica Agente alquilante Antraquinona derivado Antimetabólito Hombre Hemopatía maligna Mostaza al nitrógeno Pirimidina nucleósido
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18962718
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Anticancer research\";s:9:\"\u0000*\u0000stitle\";s:14:\"Anticancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"4C\";s:8:\"\u0000*\u0000spage\";s:4:\"2635\";s:8:\"\u0000*\u0000epage\";s:4:\"2639\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0250-7005\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"YAMAUCHI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Takahiro\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"NEGORO, Eiju\";i:1;s:14:\"UEDA, Takanori\";i:2;s:12:\"ARAI, Hajime\";i:3;s:16:\"IKEGAYA, Satoshi\";i:4;s:16:\"TAKAGI, Kazutaka\";i:5;s:18:\"TAKEMURA, Haruyuki\";i:6;s:14:\"INAI, Kunihiro\";i:7;s:14:\"YOSHIDA, Akira\";i:8;s:18:\"URASAKI, Yoshimasa\";i:9;s:18:\"IWASAKI, Hiromichi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome\";s:8:\"\u0000*\u0000place\";s:6:\"Attiki\";s:6:\"\u0000*\u0000pub\";s:46:\"International Institute of Anticancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Anticancer research\";s:9:\"\u0000*\u0000stitle\";s:14:\"Anticancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"4C\";s:8:\"\u0000*\u0000spage\";s:4:\"2635\";s:8:\"\u0000*\u0000epage\";s:4:\"2639\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0250-7005\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"YAMAUCHI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Takahiro\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"NEGORO, Eiju\";i:1;s:14:\"UEDA, Takanori\";i:2;s:12:\"ARAI, Hajime\";i:3;s:16:\"IKEGAYA, Satoshi\";i:4;s:16:\"TAKAGI, Kazutaka\";i:5;s:18:\"TAKEMURA, Haruyuki\";i:6;s:14:\"INAI, Kunihiro\";i:7;s:14:\"YOSHIDA, Akira\";i:8;s:18:\"URASAKI, Yoshimasa\";i:9;s:18:\"IWASAKI, Hiromichi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome\";s:8:\"\u0000*\u0000place\";s:6:\"Attiki\";s:6:\"\u0000*\u0000pub\";s:46:\"International Institute of Anticancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Anticancer research\";s:9:\"\u0000*\u0000stitle\";s:14:\"Anticancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"4C\";s:8:\"\u0000*\u0000spage\";s:4:\"2635\";s:8:\"\u0000*\u0000epage\";s:4:\"2639\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0250-7005\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"YAMAUCHI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Takahiro\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"NEGORO, Eiju\";i:1;s:14:\"UEDA, Takanori\";i:2;s:12:\"ARAI, Hajime\";i:3;s:16:\"IKEGAYA, Satoshi\";i:4;s:16:\"TAKAGI, Kazutaka\";i:5;s:18:\"TAKEMURA, Haruyuki\";i:6;s:14:\"INAI, Kunihiro\";i:7;s:14:\"YOSHIDA, Akira\";i:8;s:18:\"URASAKI, Yoshimasa\";i:9;s:18:\"IWASAKI, Hiromichi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome\";s:8:\"\u0000*\u0000place\";s:6:\"Attiki\";s:6:\"\u0000*\u0000pub\";s:46:\"International Institute of Anticancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Anticancer research\";s:9:\"\u0000*\u0000stitle\";s:14:\"Anticancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"4C\";s:8:\"\u0000*\u0000spage\";s:4:\"2635\";s:8:\"\u0000*\u0000epage\";s:4:\"2639\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0250-7005\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"YAMAUCHI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Takahiro\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"NEGORO, Eiju\";i:1;s:14:\"UEDA, Takanori\";i:2;s:12:\"ARAI, Hajime\";i:3;s:16:\"IKEGAYA, Satoshi\";i:4;s:16:\"TAKAGI, Kazutaka\";i:5;s:18:\"TAKEMURA, Haruyuki\";i:6;s:14:\"INAI, Kunihiro\";i:7;s:14:\"YOSHIDA, Akira\";i:8;s:18:\"URASAKI, Yoshimasa\";i:9;s:18:\"IWASAKI, Hiromichi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome\";s:8:\"\u0000*\u0000place\";s:6:\"Attiki\";s:6:\"\u0000*\u0000pub\";s:46:\"International Institute of Anticancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Anticancer research\";s:9:\"\u0000*\u0000stitle\";s:14:\"Anticancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"4C\";s:8:\"\u0000*\u0000spage\";s:4:\"2635\";s:8:\"\u0000*\u0000epage\";s:4:\"2639\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0250-7005\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"YAMAUCHI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Takahiro\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"NEGORO, Eiju\";i:1;s:14:\"UEDA, Takanori\";i:2;s:12:\"ARAI, Hajime\";i:3;s:16:\"IKEGAYA, Satoshi\";i:4;s:16:\"TAKAGI, Kazutaka\";i:5;s:18:\"TAKEMURA, Haruyuki\";i:6;s:14:\"INAI, Kunihiro\";i:7;s:14:\"YOSHIDA, Akira\";i:8;s:18:\"URASAKI, Yoshimasa\";i:9;s:18:\"IWASAKI, Hiromichi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome\";s:8:\"\u0000*\u0000place\";s:6:\"Attiki\";s:6:\"\u0000*\u0000pub\";s:46:\"International Institute of Anticancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
